Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IONS vs AGIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AGIO Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

AGIO Overall Winner 6-Pillar Tally: IONS 3 – 3 AGIO Matrix Metrics: IONS 4 – 6 AGIO

As of Nov 16, 2026, Agios Pharmaceuticals, Inc. (AGIO) is the stronger overall head-to-head candidate over Ionis Pharmaceuticals, Inc. (IONS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). IONS carries a Unified Composite Score of 63.9/100 (BUY) at $28.57 (90.9x Forward P/E, -58.8% operating margin), whereas AGIO carries 55.9/100 (HOLD) at $30.42 (2.5x Forward P/E, -297.7% operating margin).

  • Composite vs. Pillar Nuance: While IONS currently prints a higher short-term Unified Composite Score (63.9/100 BUY vs. AGIO 55.9/100 HOLD), AGIO captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-297.7% vs. -58.8% operating margin) and revenue trajectory (+330.0% vs. +54.9% YoY).
  • Technical & Structure Timing Caution: IONS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7); meanwhile AGIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IONS vs AGIO
IONS NASDAQ
Ionis Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$28.57
-1.7% 1D
Market Cap $4.7B
TTM Revenue $960M
Forward P/E 90.9x
Beta / 30D Vol 0.18β · 86% Vol
Unified Composite Score
63.9 / 100 BUY
Tech 60.0 Fund 63.0 Flow 73.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.3%), weak momentum, RSI 24
RSI-14: 23.7 · SMA20: $38.46 · SMA50: $43.07
AGIO NASDAQ Head-to-Head Winner
Agios Pharmaceuticals, Inc.
Pharmaceutical Preparations
$30.42
-3.7% 1D
Market Cap $1.9B
TTM Revenue $141M
Forward P/E 2.5x
Beta / 30D Vol 1.12β · 85% Vol
Unified Composite Score
55.9 / 100 HOLD
Tech 68.0 Fund 63.0 Flow 50.0 Mom 53.3
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -0.2%), weak momentum, RSI 43
RSI-14: 42.8 · SMA20: $33.44 · SMA50: $33.03

6-Pillar Scorecard Institutional Category Breakdown (IONS 3 – 3 AGIO)

Columns: Metric · IONS · AGIO
1. Valuation Multiples AGIO
Forward P/E 90.9x 2.5x
Trailing P/E 90.9x 2.5x
PEG Ratio N/M N/M
EV / Revenue 6.2x 13.5x
2. Growth & Scale AGIO
Revenue Growth (YoY) +54.9% +330.0%
Earnings Growth (YoY) -43.7% +0.0%
TTM Revenue (USD) $960M $141M
Market Cap $4.7B $1.9B
3. Profitability & Quality IONS
Gross Margin 3.0% N/A
Operating Margin -58.8% -297.7%
Net Profit Margin -56.9% -264.8%
Return on Equity (ROE) -108.0% -33.0%
4. Balance Sheet & Cash Flow IONS
Cash Generation (TTM) -$623M -$414M EBITDA
Cash Flow Margin -64.9% N/A
Net Cash / Leverage $1.33B Net Debt (4.14x D/E) $16.38 Book/Sh · -33.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AGIO
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 59.9% (17th %ile) 65.7% (16th %ile)
Put/Call OI Skew 1.81x (Put-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat IONS
OpEx & R&D Intensity 61.8% of Rev ($593M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IONS (4) vs AGIO (6)
Institutional Metric IONS AGIO Criterion Row Edge
Market Capitalization
Scale
$4.7B $1.9B Larger Scale IONS
Trailing P/E Ratio
Valuation
90.9x 2.5x Lower Multiple AGIO
Forward P/E Ratio
Valuation
90.9x 2.5x Lower Multiple AGIO
Revenue Growth (YoY)
Growth
+54.9% +330.0% Higher Growth AGIO
Operating Margin (TTM)
Profitability
-58.8% -297.7% Higher Margin IONS
Net Profit Margin
Profitability
-56.9% -264.8% Higher Margin IONS
Return on Equity (ROE)
Capital Efficiency
-108.0% -33.0% Higher ROE AGIO
52-Week Range Position
Momentum
2% ($27–$87) 34% ($22–$46) Stronger Trend AGIO
Beta / 30D Volatility
Risk Regime
0.18β · 86% Vol 1.12β · 85% Vol Lower Realized Risk AGIO
Unified Institutional Score
Composite Signal
63.9 / 100 (BUY) 55.9 / 100 (HOLD) Higher Composite IONS
Trailing 12M Revenue (USD)
Operating Scale
$960M $141M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
3.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.2x EV/Rev N/M PEG · 13.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$623M ($1.33B Net Debt (4.14x D/E)) -$414M EBITDA ($16.38 Book/Sh · -33.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AGIO +30.61 pp
IONS: -33.48% · AGIO: -2.87%
3M Horizon AGIO +40.52 pp
IONS: -52.09% · AGIO: -11.57%
6M Horizon AGIO +68.44 pp
IONS: -60.61% · AGIO: +7.83%
1Y Horizon AGIO +30.61 pp
IONS: -59.1% · AGIO: -28.49%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IONS vs AGIO. Trailing 12-month operating profitability (IONS -58.8% vs AGIO -297.7%) and valuation multiples (IONS 90.9x vs AGIO 2.5x Forward P/E) are benchmarked directly in Pillar 4 below.

IONS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$960M
Gross Margin3.0%
Op. Margin-58.8%
ROE / Fwd P/E-108.0% · 90.9x
AGIO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$141M
Gross MarginN/A
Op. Margin-297.7%
ROE / Fwd P/E-33.0% · 2.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IONS BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 59.9%
IV Percentile 17th %ile
Put/Call OI Skew 1.81x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact IONS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AGIO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 65.7%
IV Percentile 16th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AGIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IONS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.7B market capitalization and -58.8% operating margin.
OpEx & R&D Reinvestment 61.8% of Rev ($593M)
90D Engineering Disclosures 0 Published
AGIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.9B market capitalization and -297.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ IONS vs AGIO Key Questions & Quantitative Answers

As of Nov 16, 2026, Agios Pharmaceuticals, Inc. (AGIO) is the stronger overall head-to-head candidate over Ionis Pharmaceuticals, Inc. (IONS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). IONS carries a Unified Composite Score of 63.9/100 (BUY) at $28.57 (90.9x Forward P/E, -58.8% operating margin), whereas AGIO carries 55.9/100 (HOLD) at $30.42 (2.5x Forward P/E, -297.7% operating margin). Composite vs. Pillar Nuance: While IONS currently prints a higher short-term Unified Composite Score (63.9/100 BUY vs. AGIO 55.9/100 HOLD), AGIO captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-297.7% vs. -58.8% operating margin) and revenue trajectory (+330.0% vs. +54.9% YoY). Technical & Structure Timing Caution: IONS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7); meanwhile AGIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AGIO leads the Growth & Scale pillar: IONS posts +54.9% YoY revenue growth and -43.7% YoY earnings growth on $960M TTM revenue (3.0% gross margin, -58.8% operating margin), compared with AGIO at +330.0% YoY revenue growth and +0.0% YoY earnings growth on $141M TTM revenue (N/A gross margin, -297.7% operating margin). On trailing 12-month operating scale, IONS generates $960M in USD-normalized revenue versus $141M for AGIO. In operating R&D and SG&A reinvestment, IONS deploys 61.8% of Rev ($593M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AGIO.

AGIO screens cheaper on headline valuation multiples. IONS trades at 90.9x Forward P/E, 90.9x Trailing P/E, N/M PEG, and 6.2x EV/Revenue (-64.9% FCF margin), whereas AGIO trades at 2.5x Forward P/E, 2.5x Trailing P/E, N/M PEG, and 13.5x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IONS (-108.0% ROE) versus AGIO (-33.0% ROE) capital efficiency.

In options market volatility and institutional positioning, IONS carries 59.9% implied volatility (17th %ile, Compressed (<25th %ile)), a 1.81x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.18β · 86% Vol realized risk). By comparison, AGIO carries 65.7% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.12β · 85% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.